Tamarac, FL

Infinity Life Research Group

Asthma

Migraine Disorders

Galcanezumab

Rocatinlimab

Amgen

Lilly

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Infinity Life Research Group | Tamarac, FL

Site insights

Work at this site?

Active trials

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)

Trial sponsors